Login

An advisory panel, stacked with RFK Jr.’s pro-peptide appointees, has voted to add BPC-157 and KPV to the bulk compounding list. This is despite FDA staff clinicians stating that there’s no convincing evidence. Central to the argument is whether allowing compounding will curtail the gray market or expose the public to unnecessary risk. Internally screaming. [Media: https://www.youtube.com/live/DhDC0DAYdBI]